Epizyme
ProfileJobs

Epizyme

Suggest Edit
    • Healthbiotechoncologypharma

    Epizyme is a clinical stage biopharmaceutical company creating epigenetic therapeutics for patients with cancer. The Company is focused on creating medicines that are targeted at specific causes of diseases, that are orally administered, tolerable, easy to take, and that are based on a deep understanding of the patients that will benefit from them. 

    Based on clinical proof of concept in treating multiple forms of cancer, Epizyme's lead product candidate, tazemetostat, is being developed for hematologic malignancies and genetically defined solid tumors. The Company is also advancing novel compounds directed against a broad range of disease targets.

    Market capitalization(2018-06-14)
    $1.1 B
    Type
    Public
    HQ
    Cambridge, US
    Founded
    2007
    Size (employees)
    112 (est)
    Website
    epizyme.com
    Epizyme was founded in 2007 and is headquartered in Cambridge, US
    Report incorrect company information

    Key People/Management at Epizyme

    Robert A. Copeland

    Robert A. Copeland

    Executive Vice President and Chief Scientific Officer

    Epizyme Office Locations

    Epizyme has an office in Cambridge
    Cambridge, US (HQ)
    400 Technology Square
    Show all (1)
    Report incorrect company information

    Epizyme Financials and Metrics

    Epizyme Financials

    Epizyme's revenue was reported to be $8.01 m in FY, 2016 which is a 212.8% increase from the previous period.
    USD

    Net income (Q1, 2018)

    		(34.1 m)

    EBIT (Q1, 2018)

    		(35 m)

    Market capitalization (14-Jun-2018)

    		1.1 b

    Closing share price (14-Jun-2018)

    		15.9

    Cash (31-Mar-2018)

    		130.3 m
    Epizyme's current market capitalization is $1.1 b.
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Revenue

    		68.5 m41.4 m2.6 m8 m

    Revenue growth, %

    		(40%)(94%)213%

    General and administrative expense

    		28.4 m37.2 m

    R&D expense

    		91.5 m109.7 m
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

    General and administrative expense

    		3.6 m5 m5.3 m5.7 m5.2 m6 m6.7 m5.8 m7.4 m7.5 m8.3 m11.2 m9.3 m9.4 m

    R&D expense

    		14.6 m15.3 m17.5 m22.2 m57.1 m20.6 m16.8 m17.7 m21.5 m23.9 m24.7 m27.3 m28.7 m25.6 m

    Operating expense total

    		18.2 m20.3 m22.8 m27.9 m62.3 m26.5 m23.5 m23.6 m28.9 m31.4 m33 m38.5 m38.1 m35 m

    EBIT

    		(9.7 m)(6.9 m)(13.3 m)(19.7 m)(61.4 m)(25.8 m)(23.1 m)(23.1 m)(28.4 m)(24.8 m)(33 m)(28.5 m)(38.1 m)(35 m)
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Cash

    		123.6 m190.1 m208.3 m77.9 m226.7 m

    Accounts Receivable

    		33.7 m2.1 m262 k23 k382 k

    Inventories

    		2.4 m2.8 m4.5 m6.5 m

    Current Assets

    		159.7 m195 m213.1 m248.7 m285.8 m
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

    Cash

    		139.6 m237.1 m229.9 m211.7 m244.5 m236.7 m229.9 m312.7 m89.5 m66 m64.4 m88.5 m219.8 m130.3 m

    Accounts Receivable

    		2.2 m8.2 m2.2 m2.1 m365 k723 k177 k176 k60 k6.2 m8 k25 k25 k24 k

    Current Assets

    		143.9 m247.3 m234.7 m217.1 m247.4 m239.4 m232.6 m318.3 m296.6 m275 m220 m201.7 m317.3 m256.9 m

    PP&E

    		2 m2.6 m2.6 m2.7 m5.2 m4.9 m4.5 m3.8 m3.6 m3.3 m3.3 m3 m2.6 m2.3 m
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Net Income

    		(3.5 m)(55 m)(132.4 m)(110.2 m)(134.3 m)

    Depreciation and Amortization

    		703 k742 k1.4 m1.6 m1.6 m

    Inventories

    		(1.5 m)(419 k)(1.6 m)(1.5 m)

    Accounts Payable

    		1.6 m3.6 m(3.6 m)341 k2 m
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

    Net Income

    		(19.4 m)(6.9 m)(20.3 m)(40 m)(61.3 m)(25.8 m)(23.1 m)(22.9 m)(28 m)(24.3 m)(32.5 m)(34.1 m)

    Depreciation and Amortization

    		534 k169 k362 k548 k260 k389 k361 k

    Accounts Payable

    		364 k(1.3 m)(142 k)1.1 m(3.2 m)3 m3 m(2.4 m)3.7 m3.4 m7.3 m226 k

    Cash From Operating Activities

    		(38 m)11.9 m4.7 m(14.4 m)(22.7 m)(25.4 m)(30.3 m)
    show all
    USDY, 2018

    Financial Leverage

    		1.1 x
    Show all financial metrics
    Report incorrect company information

    Competitors

    OSE Immunotherapeutics
    Health - Public
    Alpine Immune Sciences
    Health - Private
    G1 Therapeutics
    Health - Public
    Syndax Pharmaceuticals
    Health - Public
    Compare competitors

    Epizyme Online and Social Media Presence

    Embed Graph
    Report incorrect company information

    Epizyme News and Updates

    June 18, 2018

    Epizyme (EPZM) Tazemetostat Interim Phase 2 Data in Follicular Lymphoma - Slideshow

    June 18, 2018

    Epizyme Continues To Chug Along Despite FDA Partial Clinical Hold

    May 18, 2018

    Epizyme (EPZM) Clinical Data Conference Call - Slideshow

    April 24, 2018

    Biotech Analysis Central Pharma News: Orexigen's Last Resort, Epizyme's Partial Clinical Hold, Eli Lilly And Incyte's Mixed Advisory Panel Vote

    February 22, 2018

    Synovial Sarcoma – Pipeline Review, Companies Involved in Therapeutics Development CoBioRes NV, Epizyme, GlaxoSmithKline Plc, Immune Design Corp, H1 2018

    HTF Market Report released a new research document of 49 pages on industry titled as Synovial Sarcoma - Pipeline Review, H1 2018' with detailed analysis, Competitive landscape, forecast and strategies. Posted via Industry Today. Follow us on Twitter @IndustryToday
    Report incorrect company information
    Download PDF